Singapore markets closed
Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,445.10 +159.25 (+0.25%) CMC Crypto 200
1,352.87 -7.45 (-0.55%)
PCVX Jun 2024 70.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 09:30AM EDT
| Previous close | 2.1000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 70.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.1000 - 2.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.